To test our prediction that the BIM deletion polymorphism confers a poorer clinical outcome in pediatric ALL, we conducted a retrospective analysis correlating treatment outcome with the presence of the polymorphism in a group of uniformly-treated pediatric patients from the Malaysia-Singapore (Ma-Spore) ALL 2003 multicenter study. The gene discussed is BCL2L11; the disease is acute lymphoblastic leukemia.